PubMed
Search results
Jun 29, 2024 · Peginterferon lambda-1a(ZymoGenetics, Inc.): a IFNLR1 agonists Drug, Initially developed by ZymoGenetics, Inc., Now, its global highest R&D status is Phase 3, Mechanism: IFNLR1 agonists(interferon lambda receptor 1 agonists), Therapeutic Areas: Infectious Diseases,Digestive System Disorders,Respiratory Diseases, Active Indication: COVID-19 ...
Jun 26, 2024 · ZymoGenetics - Develop protein therapies for hematology, cancer, and inflammatory disorders. Acquired by Bristol-Myers Squibb. Raisedfunding over 2 rounds from 4 investors.
Jun 22, 2024 · ZGI-04: a δ opioid receptor agonists Drug, Initially developed by ZymoGenetics, Inc., Now, its global highest R&D status is Pending, Mechanism: δ opioid receptor agonists(δ-opioid receptor agonists), Therapeutic Areas: Cardiovascular Diseases.
Jun 28, 2024 · Atacicept: a APRIL inhibitors, BAFF inhibitors Drug, Initially developed by ZymoGenetics, Inc.,
Jun 13, 2024 · Bristol Myers Squibb Completes Acquisition of Karuna Therapeutics, Strengthening Neuroscience Portfolio. 03/15/2024. FDA Advisory Committee Votes in Favor of Bristol Myers Squibb’s and 2seventy bio’s Abecma for Triple-Class Exposed Multiple Myeloma in Earlier Lines of Therapy. 03/14/2024.
Jun 27, 2024 · Explain the viral life cycle of HCV and HCV biology, with a view toward the implications for the development of targeted therapies for the treatment of hepatitis C. Evaluate the potential efficacy and safety of these targeted emerging/investigational therapies for hepatitis C on the basis of early data.
Jun 23, 2024 · Received grants for clinical research from: Genentech, Inc.; Gilead Sciences, Inc.; Pharmasset, Inc.; Tibotec, Inc.; Vertex Pharmaceuticals Incorporated; ZymoGenetics, Inc.
